medinfoАктуальные проблемы теоретической и клинической медициныActual Problems of Theoretical and Clinical Medicine2790-12892790-1297Казахстанско-Российский медицинский университет10.24412/2790-1289-2025-2-144-153medinfo-739Research ArticleОБЗОР ЛИТЕРАТУРЫREVEWSРОЛЬ НЕСЕЛЕКТИВНЫХ Β-БЛОКАТОРОВ И СОМАТОСТАТИНА ПРИ ЛЕЧЕНИИ КРОВОТЕЧЕНИЙ ИЗ ВАРИКОЗНЫХ ВЕН ПРИ ЦИРРОЗЕ ПЕЧЕНИTHE ROLE OF NONSELECTIVE Beta-BLOCKERS AND SOMATOSTATIN IN THE TREATMENT OF VARICOSE VEIN BLEEDING IN CIRRHOSIS OF THE LIVERhttps://orcid.org/0009-0002-3043-1170ИсмайловМ. К.IsmailovM. K.

Исмайлов Мұса Кенжеғалиұлы – докторант; врач-хирург отделения хирургии

Алматы

Ismailov Musa Kenzhegaliuly – doctoral student; physician - surgeon of the surgery department of the Municipal state enterprise under the right of economic management under the right of economic management

Almaty

musa_ismailov_97@list.ruhttps://orcid.org/0000-0002-4559-1276КузикеевМ. А.KuzikeevM. A.

Кузикеев Марат Анатольевич – доктор медицинских наук, доцент кафедры «Хирургии с курсом анестезиологии и реаниматологии»

Алматы

Kuzikev Marat Anatolyevich – Doctor of Medical Sciences, Associate Professor of the Department of Surgery with a Course in Anesthesiology and Resuscitation, Oncologist, Abdominal Surgeon

Almaty

a.torotot@mail.ruhttps://orcid.org/0000-0001-9510-4096ЖанталиноваН. А.ZhantalinovaN. A.

Жанталинова Нуржамал Асеновна – д.м.н., асс. профессор кафедры «Хирургии с курсом анестезиологии и реаниматологии», врач – хирург отделения хирургии

Алматы

Zhantalinova Nurzhamal Asenovna – Doctor of Medical Sciences, Associate Professor of the Department of Surgery with a Course in Anesthesiology and Resuscitation; Surgeon of the Department of Surgery

Almaty

doctor-nurzhamal@mail.ruНУО «Казахстанско-Российский медицинский университет»КазахстанNEI «Kazakh-Russian Medical University»KazakhstanНУО «Казахстанско-Российский медицинский университет»; КГП на ПХВ «Городская больница скорой неотложной помощи» УЗКазахстанNEI «Kazakh-Russian Medical University»; «City Emergency Hospital» MSE REM under the Almaty City Health DepartmentKazakhstan20250607202502144153Copyright © Исмайлов М.К., Кузикеев М.А., Жанталинова Н.А., 20252025Исмайлов М.К., Кузикеев М.А., Жанталинова Н.А.Ismailov M.K., Kuzikeev M.A., Zhantalinova N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://kazrosmedjournal.krmu.edu.kz/jour/article/view/739

Цирроз печени часто сопровождается портальной гипертензией, провоцирующей опасные варикозные кровотечения пищевода и желудка. Несвоевременная остановка кровотечения приводит к высокой смертности. В терапии активно применяются неселективные β-блокаторы и соматостатин.

Материалы и методы

Материалы и методы. Проведен литературный обзор за последние 25 лет с использованием баз данных Google Scholar, PubMed и др. Отобрано 20 релевантных источников, соответствующих критериям включения.

Цель исследования

Цель исследования. Проанализировать комбинированное лечение в виде неселективных блокаторов β-рецепторов и соматостатина в лечении кровотечений из варикозно-расширенных вен пищевода и желудка при циррозе печени.

Результаты

Результаты. Неселективные β-блокаторы, такие как пропранолол, снижают портальное давление, частоту сердечных сокращений и сердечный выброс. Соматостатин уменьшает висцеральный кровоток и ингибирует вазодилатацию, способствуя остановке кровотечения. Совместное применение данных препаратов снижает риск повторных кровотечений и развития гепаторенального синдрома эффективнее, чем монотерапия.

Выводы

Выводы. Совместное использование неселективных β-блокаторов и соматостатина повышает эффективность лечения варикозных кровотечений при циррозе печени и снижает риск осложнений.

Cirrhosis of the liver is often accompanied by portal hypertension, which causes dangerous varicose veins of the esophagus and stomach. Untimely stop of bleeding leads to high mortality. Nonselective betablockers and somatostatin are actively used in therapy.

The purpose of the study

The purpose of the study. Тo analyze the combined treatment of nonselective beta-receptor blockers and somatostatin in the treatment of bleeding from varicose veins of the esophagus and stomach in cirrhosis of the liver.

Мaterials and Methods

Мaterials and Methods: A literature review conducted over the past 25 years in Google Scholar, PubMed, and other databases revealed 20 relevant sources. The selected sources meet the inclusion criteria.

Results

Results: NSB, like propranolol, reduces portal pressure, heart rate, and cardiac output. Somatostatin reduces visceral blood flow and inhibits vasodilation, helping to stop bleeding. The combined use of these drugs reduces the risk of recurrent bleeding and the development of hepatorenal syndrome more effectively than monotherapy.

Conclusions

Conclusions: The combined use of NSB and somatostatin increases the effectiveness of the treatment of varicose veins in cirrhosis of the liver and reduces the risk of complications

цирроз печеникровотечениеварикозно-расширенные венынеселективные блокаторыβ-рецепторысоматостатингепаторенальный синдромcirrhosis of the liverbleedingvaricose veinsnonselective blockersbeta-receptorssomatostatinhepatorenal syndromeReferencesИвашкин В. Т., Маевская М. В., Павлов Ч. С. Диагностика и лечение неалкогольной жировой болезни печени: Клинические рекомендации Российского научного общества по заболеваниям печени и Российского гастроэнтерологического общества // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2016. – Т. 26. – № 2. – С. 24- 42. – DOI: 10.22416/1382 4376 2016 26 2 24 42pubmed.ncbi.nlm.nih.gov+4ouci.dntb.gov.ua+4doaj.org+4.Ivashkin, V. T., Maevskaya, M. V., & Pavlov, C. S. (2016). Diagnostika i lechenie nealkogol'noj zhi- rovoj bolezni pecheni: Klinicheskie rekomendacii Rossijskogo nauchnogo obshhestva po zabolevanijam pecheni i Rossijskogo gastrojenterologicheskogo obshhestva. Russian Journal of Gastroenterology, Hepatology, Coloproctology, 26(2), 24-42. DOI: https://doi.org/10.22416/1382-4376-2016-26-2-24-42 (In Russian).Mukomolov S. L., Trifonova G., Levakova I. А., Bolsun D., Krivanogova Е. G. Hepatitis C in the Russian Federation: challenges and future directions // Hepatic Medicine: Evidence and Research. – 2016. – Vol. 8. – P. 51-60. – DOI: 10.2147/HMER.S50172Mukomolov, S. L., Trifonova, G., Levakova, I. A., Bolsun, D., & Krivanogova, E. G. (2016). Hepatitis C in the Russian Federation: Challenges and future directions. Hepatic Medicine: Evidence and Research, 8, 51-60. DOI: https://doi.org/10.2147/HMER.S50172.Kleber G., Sauerbruch T. Concomitant gastric varices: bleeding risk sign in patients with liver cirrhosis and esophageal varices? // Gastroenterology. – 2018. – Vol. 155(5). – P. 1648-1649. – DOI: 10.1053/j.gastro.2018.05.053.Kleber, G., & Sauerbruch, T. (2018). Concomitant gastric varices: Bleeding risk sign in patients with liver cirrhosis and esophageal varices? Gastroenterology, 155(5), 1648-1649. DOI: https://doi.org/10.1053/j.gastro.2018.05.053.Sarin S. K., Choudhury A., Sharma M. K., et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update // Hepatology International. – 2019. – Vol. 13(4). – P. 353- 390. – DOI: 10.1007/s12072-019-09946-3.Sarin, S. K., Choudhury, A., Sharma, M. K., et al. (2019). Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): An update. Hepatology International, 13(4), 353-390. DOI: https://doi.org/10.1007/s12072-019-09946-3.Loffroy R., Estivalet L., Cherblanc V., et al. Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage // World Journal of Gastroenterology: WJG. – 2013. – Vol. 19(37). – P. 6131-6143. – DOI: 10.3748/wjg.v19.i37.6131.Loffroy, R., Estivalet, L., Cherblanc, V., et al. (2013). Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage. World Journal of Gastroenterology, 19(37), 6131-6143. DOI: https://doi.org/10.3748/wjg.v19.i37.6131.Tseng Y., Li F., Wang J., et al. Spleen and liver stiffness for noninvasive assessment of portal hypertension in cirrhotic patients with large esophageal varices // Journal of Clinical Ultrasound. – 2018. – Vol. 46(7). – P. 442-449. – DOI: 10.1002/jcu.22635.Tseng, Y., Li, F., Wang, J., et al. (2018). Spleen and liver stiffness for noninvasive assessment of portal hypertension in cirrhotic patients with large esophageal varices. Journal of Clinical Ultrasound, 46(7), 442-449. DOI: https://doi.org/10.1002/jcu.22635.Lu Y. Y., Gao J. H., Zhao C., Wen S. L., Tang C. W., Wang Y. F. Cyclooxygenase-2 upregulates hepatic somatostatin receptor 2 expression // Scientific Reports. – 2018. – Vol. 8(1). – P. 1-11. – DOI: 10.1038/s41598-018-29349-y.Lu, Y. Y., Gao, J. H., Zhao, C., Wen, S. L., Tang, C. W., & Wang, Y. F. (2018). Cyclooxygenase-2 upregulates hepatic somatostatin receptor 2 expression. Scientific Reports, 8(1), 1-11. DOI: https://doi.org/10.1038/s41598-018-29349-y.Mandorfer M., Reiberger T. Beta blockers and cirrhosis, 2016 // Digestive and Liver Disease. – 2017. – Vol. 49(1). – P. 3-10. – DOI: 10.1016/j.dld.2016.09.013.Mandorfer, M., & Reiberger, T. (2017). Beta blockers and cirrhosis, 2016. Digestive and Liver Disease, 49(1), 3-10. DOI: https://doi.org/10.1016/j.dld.2016.09.013.Rodrigues S. G., Mendoza Y. P., Bosch J. Betablockers in cirrhosis: evidence-based indications and limitations // JHEP Reports. – 2020. – Vol. 2(1). – P. 100063. – DOI: 10.1016/j.jhepr.2019.12.001.Rodrigues, S. G., Mendoza, Y. P., & Bosch, J. (2020). Beta-blockers in cirrhosis: Evidencebased indications and limitations. JHEP Reports, 2(1), 100063. DOI: https://doi.org/10.1016/j.jhepr.2019.12.001.Jakab S. S., Garcia-Tsao G. Evaluation and management of esophageal and gastric varices in patients with cirrhosis // Clinics in Liver Disease. – 2020. – Vol. 24(3). – P. 335-350. – DOI: 10.1016/j.cld.2020.04.011.Jakab, S. S., & Garcia-Tsao, G. (2020). Evaluation and management of esophageal and gastric varices in patients with cirrhosis. Clinics in Liver Disease, 24(3), 335-350. DOI: https://doi.org/10.1016/j.cld.2020.04.011.Francoz C., Durand F., Kahn J. A., Genyk Y. S., Nadim M. K. Hepatorenal syndrome // Clinical Journal of the American Society of Nephrology. – 2019. – Vol. 14(5). – P. 774-781. – DOI: 10.2215/CJN.12451018.Francoz, C., Durand, F., Kahn, J. A., Genyk, Y. S., & Nadim, M. K. (2019). Hepatorenal syndrome. Clinical Journal of the American Society of Nephrology, 14(5), 774-781. DOI: https://doi.org/10.2215/CJN.12451018.Nand N., Verma P., Jain D. Comparative evaluation of continuous venovenous hemodiafiltration and continuous arterio-venous hemodiafiltration in patients of hepatic failure and/or hepatorenal syndrome // The Journal of the Association of Physicians of India. – 2019. – Vol. 67(67). – P. 39-42.Nand, N., Verma, P., & Jain, D. (2019). Comparative evaluation of continuous veno-venous hemodiafiltration and continuous arterio-venous hemodiafiltration in patients of hepatic failure and/or hepatorenal syndrome. The Journal of the Association of Physicians of India, 67(67), 39-42.Tapper E. B., Parikh N. D. Diagnosis and management of cirrhosis and its complications: A review // JAMA. – 2023. – Vol. 329(18). – P. 1589- 1602. – DOI: 10.1001/jama.2023.5997.Tapper, E. B., & Parikh, N. D. (2023). Diagnosis and management of cirrhosis and its complications: A review. JAMA, 329(18), 1589-1602. DOI: https://doi.org/10.1001/jama.2023.5997.Mauro E., Gadano A. What’s new in portal hypertension? // Liver International. – 2020. – Vol. 40(1). – P. 122-127. – DOI: 10.1111/liv.14366.Mauro, E., & Gadano, A. (2020). What’s new in portal hypertension? Liver International, 40(Suppl. 1), 122-127. DOI: https://doi.org/10.1111/liv.14366.Pose E., Piano S., Juanola A., Ginès P. Hepatorenal syndrome in cirrhosis // Gastroenterology. – 2024. – Vol. 166(4). – P. 588-604. – DOI: 10.1053/j.gastro.2023.11.306.Pose, E., Piano, S., Juanola, A., & Ginès, P. (2024). Hepatorenal syndrome in cirrhosis. Gastroenterology, 166(4), 588-604. https://doi.org/10.1053/j.gastro.2023.11.306.Gupta K., Bhurwal A., Law C., Ventre S., Minacapelli C. D., Kabaria S., Li Y., Tait C., Catalano C., Rustgi V. K. Acute kidney injury and hepatorenal syndrome in cirrhosis // World Journal of Gastroenterology. – 2021. – Vol. 27(26). – P. 3984-4003. – DOI: 10.3748/wjg.v27.i26.3984.Gupta, K., Bhurwal, A., Law, C., Ventre, S., Minacapelli, C. D., Kabaria, S., Li, Y., Tait, C., Catalano, C., & Rustgi, V. K. (2021). Acute kidney injury and hepatorenal syndrome in cirrhosis. World Journal of Gastroenterology, 27(26), 3984-4003. DOI: https://doi.org/10.3748/wjg.v27.i26.3984.He X., Dai Z., Shi P., Hong J. Intravenous drip of somatostatin followed by restricted fluid resuscitation to treat upper gastrointestinal bleeding in patients with liver cirrhosis // EvidenceBased Complementary and Alternative Medicine. – 2021. – Vol. 2021. – Article No. 6548479. – DOI: 10.1155/2021/6548479.He, X., Dai, Z., Shi, P., & Hong, J. (2021). Intravenous drip of somatostatin followed by restricted fluid resuscitation to treat upper gastrointestinal bleeding in patients with liver cirrhosis. Evidence-Based Complementary and Alternative Medicine, 2021, 6548479. DOI: https://doi.org/10.1155/2021/6548479.Liu X., Guo X., Zhou H. Octreotide acetate combined with somatostatin upregulates miR-1291 and downregulates miR-331-3p in patients with cirrhosis and upper gastrointestinal bleeding // American Journal of Translational Research. – 2021. – Vol. 13(8). – P. 9883-9891.Liu, X., Guo, X., & Zhou, H. (2021). Octreotide acetate combined with somatostatin upregulates miR-1291 and downregulates miR-331-3p in patients with cirrhosis and upper gastrointestinal bleeding. American Journal of Translational Research, 13(8), 9883-9891.Albillos A., Krag A. Beta-blockers in the era of precision medicine in patients with cirrhosis // Journal of Hepatology. – 2023. – Vol. 78(4). – P. 866-872. – DOI: 10.1016/j.jhep.2022.12.005.Albillos, A., & Krag, A. (2023). Beta-blockers in the era of precision medicine in patients with cirrhosis. Journal of Hepatology, 78(4), 866-872. DOI: https://doi.org/10.1016/j.jhep.2022.12.005.Møller S., Danielsen K. V., Nabilou P., Kimer N., Bendtsen F. Beta-adrenergic blockade in cirrhosis – harmful or helpful? // Expert Review of Gastroenterology & Hepatology. – 2023. – Vol. 17(6). – P. 519-529. – DOI: 10.1080/17474124.2023.2215428.Møller, S., Danielsen, K. V., Nabilou, P., Kimer, N., & Bendtsen, F. (2023). Beta-adrenergic blockade in cirrhosis – Harmful or helpful? Expert Review of Gastroenterology & Hepatology, 17(6), 519-529. DOI: https://doi.org/10.1080/17474124.2023.2215428.Burza M. A., Marschall H. U., Napoleone L., Molinaro A. The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight? // Pharmacological Research. – 2017. – Vol. 119. – P. 20- 26. – DOI: 10.1016/j.phrs.2017.01.015.Burza, M. A., Marschall, H. U., Napoleone, L., & Molinaro, A. (2017). The 35-year odyssey of beta blockers in cirrhosis: Any gender difference in sight? Pharmacological Research, 119, 20-26. DOI: https://doi.org/10.1016/j.phrs.2017.01.015.Mao G., Li C., Wang H., Jv Y. H., Zhang Y., Liu L. Exploration on the effect of nonselective β-receptor blockers (NSBBs) on hemodynamic parameters in complicated liver cirrhosis // BioMed Research International. – 2022. – Vol. 2022. – Article No. 7922906. – DOI: 10.1155/2022/7922906.Mao, G., Li, C., Wang, H., Jv, Y. H., Zhang, Y., & Liu, L. (2022). Exploration on the effect of nonselective β-receptor blockers (NSBBs) on hemodynamic parameters in complicated liver cirrhosis. BioMed Research International, 2022, 7922906. DOI: https://doi.org/10.1155/2022/7922906.Garbuzenko D. V. Contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis patients // World Journal of Hepatology. – 2024. – Vol. 16(2). – P. 126-134. – DOI: 10.4254/wjh.v16.i2.126.Garbuzenko, D. V. (2024). Contemporary concepts of prevention and management of gastroesophageal variceal bleeding in liver cirrhosis patients. World Journal of Hepatology, 16(2), 126- 134. DOI: https://doi.org/10.4254/wjh.v16.i2.126.Gracia-Sancho J., Maeso-Díaz R., Bosch J. Pathophysiology and a rational basis of therapy // Digestive Diseases. – 2015. – Vol. 33(4). – P. 508- 514. – DOI: 10.1159/000374099.Gracia-Sancho, J., Maeso-Díaz, R., & Bosch, J. (2015). Pathophysiology and a rational basis of therapy. Digestive Diseases, 33(4), 508-514. DOI: https://doi.org/10.1159/000374099. 25. Nair, H., Berzigotti, A., & Bosch, J. (2016). Emerging therapies for portal hypertension in cirrhosis. Expert Opinion on Emerging Drugs, 21(2), 167-181. h DOI: ttps://doi.org/10.1080/14728214.2016.1184647.Nair H., Berzigotti A., Bosch J. Emerging therapies for portal hypertension in cirrhosis // Expert Opinion on Emerging Drugs. – 2016. – Vol. 21(2). – P. 167-181. – DOI: 10.1080/14728214.2016.1184647.Gracia-Sancho, J., Maeso-Díaz, R., Fernández-Iglesias, A., Navarro-Zornoza, M., & Bosch, J. (2015). New cellular and molecular targets for the treatment of portal hypertension. Hepatology International, 9(2), 183-191. DOI: https://doi.org/10.1007/s12072-015-9613-5.Gracia-Sancho J., Maeso-Díaz R., FernándezIglesias A., Navarro-Zornoza M., Bosch J. New cellular and molecular targets for the treatment of portal hypertension // Hepatology International. – 2015. – Vol. 9(2). – P. 183-191. – DOI: 10.1007/s12072-015-9613-5.Snyder, P., Ali, R., Poles, M., & Gross, S. A. (2015). Portal hypertensive gastropathy with a focus on management. Expert Review of Gastroenterology & Hepatology, 9(9), 1207-1216. DOI: https://doi.org/10.1586/17474124.2015.1059275.Snyder P., Ali R., Poles M., Gross S. A. Portal hypertensive gastropathy with a focus on management // Expert Review of Gastroenterology & Hepatology. – 2015. – Vol. 9(9). – P. 1207-1216. – DOI: 10.1586/17474124.2015.1059275.Snyder P., Ali R., Poles M., Gross S. A. Portal hypertensive gastropathy with a focus on management // Expert Review of Gastroenterology & Hepatology. – 2015. – Vol. 9(9). – P. 1207-1216. – DOI: 10.1586/17474124.2015.1059275.

The authors declare that there are no conflicts of interest present.